FDA turns down J&J drug for uncommon blood-pooling complication in patients with stents

J&J subsidiary seeks approval for prevention of stent thrombosis

RARITAN, N.J. — The Food and Drug Administration has declined to approve a drug made by Johnson & Johnson for patients who have received coronary stent implants.

J&J subsidiary Janssen Research & Development said Friday that the FDA issued a complete response letter for Xarelto (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome. Stent thrombosis is when blood pools at the site of a stent in the patient's coronary artery and, while uncommon, is serious and can cause a heart attack and death.

The FDA issues a complete response letter when it has finished reviewing a drug application, but questions remain that preclude final approval, and Janssen said it would continue discussions with the FDA. Xarelto is already approved for treating certain blood clots.

 

Recommended stories

Comments

- 2:42 PM
Sarah says

I applaud the FDA, as a nurse
I applaud the FDA, as a nurse assistant from Florida, they approve way to much as it is. read more

Login or Register to post a comment.